Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip100: Indian firms up R&D spend, ascend value chain

This article was originally published in Scrip

Executive Summary

The R&D spends of a clutch of frontline Indian firms have seen a significant uptick over the past few years, seemingly in line with their growing emphasis on complex therapy and limited competition areas as well as the efforts of some to make a mark in the biosimilars space.

You may also be interested in...



India’s COVID-19 Nightmare And How Pharma Is Holding Up

A COVID-19 second wave is wreaking havoc in India but pharma appears to be holding things together for now, stretching resources amid a dip in personnel attendance and supply chain strains. Limited vaccine supplies, a spurt in API prices and an inevitable third wave could mean further turbulence ahead.

As Natco Ups The Ante Lilly Readies Voluntary Licensing For Olumiant

Eli Lilly responds with baricitinib donation plan and efforts to sew up royalty free voluntary licenses with local Indian firms as challenger Natco seeks a compulsory license for its version of the JAK inhibitor, which it is ready to launch.

Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'

Biocon is still awaiting a site inspection as pandemic-related delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes it can still make good and garner market share. All eyes are also on traction for its insulin glargine via increased share of formulary contracts.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel